Impax Asset Management’s AstraZeneca AZN Stock Holding History

Impax Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-7,800	Closed	-$506K	–	186
2014 Q1	$506K	Sell	7,800 -19,600	-72%	-$1.27M	0.03%	181
2013 Q4	$1.63M	Buy	27,400 +3,200	+13%	+$174K	0.1%	123
2013 Q3	$1.26M	Buy	24,200 +10,600	+78%	+$532K	0.08%	139
2013 Q2	$643K	Buy	+13,600	New	+$693K	0.04%	161

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

MCM

Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Impax Asset Management's AZN Position: Q2 2014 in Review

Impax Asset Management sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 7,800 shares — an estimated $506K sold.

Impax Asset Management first reported a position in AZN in Q2 2013 and held it in 4 quarters. The position peaked at $1.63M in Q4 2013. 419 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

Impax Asset Management reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
Impax Asset Management sold 7,800 AstraZeneca shares in Q2 2014, an estimated $506K.
Impax Asset Management first reported a position in AstraZeneca in Q2 2013 and held it in 4 quarters.
Impax Asset Management's AstraZeneca position peaked at $1.63M in Q4 2013.
419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on Impax Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.